Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

Group 1 - Verrica Pharmaceuticals Inc. reported quarterly earnings of $0.02 per share, exceeding the Zacks Consensus Estimate of a loss of $0.7 per share, and showing a significant improvement from a loss of $3.1 per share a year ago, resulting in an earnings surprise of +102.86% [1] - The company achieved revenues of $12.7 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 154.04%, compared to revenues of $5.18 million in the same quarter last year [2] - Over the last four quarters, Verrica Pharmaceuticals has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2 - The stock has underperformed the market, losing about 4.3% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the upcoming quarter is -$0.60 on $7 million in revenues, and for the current fiscal year, it is -$3.00 on $21.7 million in revenues [7] Group 3 - The Medical - Drugs industry, to which Verrica Pharmaceuticals belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, IGC Pharma, Inc., is expected to report a quarterly loss of $0.03 per share, with revenues projected to be $0.33 million, reflecting a 22.2% increase from the year-ago quarter [9]